Moss Adams Wealth Advisors LLC Increases Position in Johnson & Johnson (NYSE:JNJ)

Moss Adams Wealth Advisors LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 47.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,293 shares of the company's stock after buying an additional 3,295 shares during the period. Moss Adams Wealth Advisors LLC's holdings in Johnson & Johnson were worth $1,489,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. State Street Corp increased its position in shares of Johnson & Johnson by 0.9% in the 3rd quarter. State Street Corp now owns 134,245,811 shares of the company's stock valued at $21,755,874,000 after purchasing an additional 1,154,088 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Johnson & Johnson by 1.8% during the third quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company's stock worth $9,064,149,000 after purchasing an additional 1,004,763 shares in the last quarter. FMR LLC increased its holdings in Johnson & Johnson by 7.4% in the third quarter. FMR LLC now owns 18,316,920 shares of the company's stock valued at $2,968,440,000 after buying an additional 1,265,748 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock worth $2,858,543,000 after buying an additional 102,502 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Johnson & Johnson by 11.4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock worth $2,721,355,000 after acquiring an additional 1,729,281 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $1.07 during trading on Tuesday, reaching $148.10. The company had a trading volume of 11,094,063 shares, compared to its average volume of 8,798,511. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock's fifty day moving average price is $148.35 and its 200 day moving average price is $156.11. The firm has a market capitalization of $356.57 billion, a price-to-earnings ratio of 21.43, a price-to-earnings-growth ratio of 2.39 and a beta of 0.51.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.35%. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company's stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

JNJ has been the topic of several research analyst reports. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an "outperform" rating and a $190.00 target price on the stock. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Bank of America decreased their price objective on shares of Johnson & Johnson from $166.00 to $160.00 and set a "neutral" rating for the company in a research note on Friday. Finally, Guggenheim lifted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $173.27.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.